Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk

Table 7

Some of the published GWASs on CRC (100).

Reference SNP (rs)	Gene or region	Population	Sample size for stage	Sample size for subsequent stages	Genotyping platform (Nb. of SNPs)	Study reference
rs4939827	18q21 SMAD7	First stage: UK	940 cases/965 controls	7473 cases/5984 controls	Affymetrix (550,163)	(101)
		Second stage: UK
rs6983267	8q24	First stage: UK	930 cases/960 controls	7334 cases/5246 controls	Illumina (547,647)	(102)
		Second stage: UK
rs10505477	8q24	First stage: Canada	1257 cases/1336 controls	4024 cases/4042 controls	Illumina and Affymetrix (99,632)	(103)
rs719725	9p24	Other stages: Canada, US, and Scotland
rs4779584	15q13 CRAC1	First stage: UK	730 cases/960 controls	4500 cases/3860 controls	Illumina (547,647)	(104)
		Second stage: UK
rs4939827	18q21 SMAD7	First stage: Scotland	98 cases/1002 controls	16476 cases/15351 controls	Illumina (541,628)	(105)
rs7014346	8q24	Second stage and replication: Canada, UK, Israel, Japan, and EU
rs3802842	11q23
rs4444235	14q22.2 BMP4	First stage: UK	6780 cases/6843 controls	13406 cases/14012 controls	Multiple (38,710)	(106)
rs9929218	16q22.1 CDH1	Replication: EU, Canada
rs10411210	19q13 RHPN2
rs961253	20p12.3